Condition: Renal Cell Carcinoma · Ovarian Cancer · Cervix Cancer · Sponsor: Chongqing Precision Biotech Co., Ltd
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
This description comes directly from the study's public registry record.
Fei Li, M.D · 13970038386 · 691058841@qq.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06010875